The total number of new T1-Hypo-Intense Lesions Chronic Black Holes for all participants in the treatment group was calculated as the sum of the individual number of new lesions at Weeks 24, 48, and Brain volume was recorded as an absolute "normalized" value at the baseline visit then recorded at subsequent visits as a percentage change relative to the absolute value at the baseline visit. The SF is a multi-purpose, short-form health survey with 36 questions.
AUC represents total drug exposure for one dosing interval after the 4th dose. Number of participants positive for anti-drug antibodies ADAs to ocrelizumab is the number of post- baseline evaluable participants determined to have treatment-induced ADA or treatment-enhanced ADA during the study period. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Contacts and Locations.
Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials. Lang, Prof. Schreiber, Dr. Universitaria S. Maciejowscy SC. Petersburg State Medical University n.
Beata Dupejova Neurologicka ambulancia s. More Information. Publications automatically indexed to this study by ClinicalTrials. Risk of requiring a walking aid after 6.
Eur J Neurol. Epub Jul JAMA Neurol. N Engl J Med. Epub Dec National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Relapsing Multiple Sclerosis. Phase 3. Study Type :. Those in the remdesivir-only group will receive a matching placebo subcutaneous injection every other day for a total of four doses during hospitalization.
Investigators will evaluate whether time to recovery is shorter in the combination therapy group relative to the remdesivir-only group. Recovery is defined as the participant being well enough for hospital discharge, meaning the participant either no longer requires supplemental oxygen or ongoing medical care in the hospital, or is no longer hospitalized with or without some limitation on activities.
Recovery is evaluated up until day A key secondary goal of the study is to compare patient outcomes at day 15 using an ordinal eight-point scale ranging from fully recovered to death. The trial also will compare other secondary outcome variables between treatment groups, including mortality alone. An independent data and safety monitoring board DSMB will monitor ongoing results to ensure patient well-being and safety as well as study integrity.
Preliminary results are expected in the fall of A product licensed to Eli Lilly and Company by Incyte and marketed under the brand name Olumiant, baricitinib is approved in the U.
NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases.
For more information about NIH and its programs, visit www. Results First Posted : September 20, Last Update Posted : September 20, Study Description. MedlinePlus related topics: Flu Multiple Sclerosis. Drug Information available for: Interferon beta-1a Avonex. FDA Resources. Arms and Interventions.
Outcome Measures. HADS was used to measure depression and anxiety in subjects. FSS is a method designed to assess disabling fatigue in all the individuals. PSQI is a self-rated questionnaire which assess sleep quality and disturbances over a 1-month interval using seven clinically derived components of sleep difficulties: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. The MusiQoL is a validated item questionnaire describing 9 dimensions: activities of daily living 8 items ; psychological well-being 4 items ; symptoms 3 items ; relationships with friends 4 items ; relationships with family 3 items ; relationship with healthcare system 3 items ; sentimental and sexual life 2 items ; coping 2 items ; and rejection 2 items.
Adherence to treatment was calculated as x the number of completed injections the subject administered divided by the expected number of injections. Results are presented for three cytokines: leptin, resistin and adiponectin. Correlation was assessed by using Pearson correlation coefficient.
Results are presented for cytokines: leptin and resistin. An adverse event AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Inclusion Criteria: Males and females between 18 and 60 years of age Female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential.
Furthermore, female subjects must not have been pregnant from at least three months prior to enter in the study Subjects have RMS according to the revised McDonald Criteria Subjects with an expanded disability status scale EDSS score of less than 6.
Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.
0コメント